revumenib Revuforj
Selected indexed studies
- Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). (J Clin Oncol, 2025) [PMID:39121437]
- Revumenib: First Approval. (Drugs, 2025) [PMID:40072775]
- The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. (Nature, 2023) [PMID:36922593]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Revumenib: First Approval. (2025) pubmed
- Acute myeloid leukemia management and research in 2025. (2025) pubmed
- Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). (2025) pubmed
- The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. (2023) pubmed
- Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. (2025) pubmed
- Revumenib (Revuforj) for acute leukemia. (2025) pubmed
- MEN1 mutations mediate clinical resistance to menin inhibition. (2023) pubmed
- Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML. (2025) pubmed
- Revumenib. (2006) pubmed
- Revumenib. (2012) pubmed